- Home
- OPRT vs CLLS Comparison
OPRT vs CLLS Comparison
Compare OPRT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRT
- CLLS
- Stock Information
- Founded
- OPRT 2005
- CLLS 1999
- Country
- OPRT United States
- CLLS France
- Employees
- OPRT N/A
- CLLS N/A
- Industry
- OPRT Finance: Consumer Services
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- OPRT Finance
- CLLS Health Care
- Exchange
- OPRT Nasdaq
- CLLS Nasdaq
- Market Cap
- OPRT 221.5M
- CLLS 144.4M
- IPO Year
- OPRT 2019
- CLLS 2007
- Fundamental
- Price
- OPRT $6.15
- CLLS $1.53
- Analyst Decision
- OPRT Hold
- CLLS Buy
- Analyst Count
- OPRT 2
- CLLS 3
- Target Price
- OPRT $5.00
- CLLS $7.00
- AVG Volume (30 Days)
- OPRT 313.8K
- CLLS 84.6K
- Earning Date
- OPRT 05-08-2025
- CLLS 05-27-2025
- Dividend Yield
- OPRT N/A
- CLLS N/A
- EPS Growth
- OPRT N/A
- CLLS N/A
- EPS
- OPRT N/A
- CLLS N/A
- Revenue
- OPRT $763,617,000.00
- CLLS $49,217,000.00
- Revenue This Year
- OPRT $28.71
- CLLS $48.52
- Revenue Next Year
- OPRT $9.89
- CLLS $5.17
- P/E Ratio
- OPRT N/A
- CLLS N/A
- Revenue Growth
- OPRT N/A
- CLLS 435.38
- 52 Week Low
- OPRT $2.37
- CLLS $1.10
- 52 Week High
- OPRT $9.25
- CLLS $3.32
- Technical
- Relative Strength Index (RSI)
- OPRT 66.08
- CLLS 56.17
- Support Level
- OPRT $4.77
- CLLS $1.54
- Resistance Level
- OPRT $5.68
- CLLS $1.65
- Average True Range (ATR)
- OPRT 0.30
- CLLS 0.08
- MACD
- OPRT 0.16
- CLLS -0.00
- Stochastic Oscillator
- OPRT 96.26
- CLLS 58.62
About OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.